Asadollahi Neda, Rahaie Mahdi, Moradifar Fatemeh
Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, 14399-57131, Iran.
J Fluoresc. 2024 Aug 12. doi: 10.1007/s10895-024-03898-0.
Breast cancer is the most common cancer and the second cause of cancer-related death in women, especially in the age of 20-59 years. It is very important to diagnose it in the early stages of development due to high chance of survival. In this research, the early detection of two microRNAs involved in breast cancer including miR-21 and miR-155 was performed simultaneously using a nanobiosensor based on a special G-quadruplex structure and a colorimetric manner. This nanobiosensor contains two probes (p1, p2) that play a role in the formation of a special structure called DNA-G4. This structure has peroxidase-like properties and can oxidize TMB and produce a blue color. The diagnostic method is designed as a signal off, where the hybridization of probes with microRNA sequences, no DNA-G4 structure is formed and no color change is observed. The results of this study showed that the linear range of response is in the range of 2 to 10 nm and limit of detection in buffer, blood and urine samples was calculated as 0.43 nM, 0.54 nM, and 0.62 nM (R = 0.98), respectively. Evaluation using the method for cancer monitoring can be a simple, fast and cost-effective technique.
乳腺癌是女性中最常见的癌症,也是癌症相关死亡的第二大原因,尤其是在20至59岁的女性中。由于生存几率高,在其发展的早期阶段进行诊断非常重要。在本研究中,基于一种特殊的G-四链体结构和比色法,使用纳米生物传感器同时对两种参与乳腺癌的微小RNA(miR-21和miR-155)进行早期检测。这种纳米生物传感器包含两个探针(p1、p2),它们在形成一种名为DNA-G4的特殊结构中发挥作用。这种结构具有类似过氧化物酶的特性,能够氧化TMB并产生蓝色。该诊断方法设计为信号关闭,即探针与微小RNA序列杂交时,不会形成DNA-G4结构,也不会观察到颜色变化。本研究结果表明,响应的线性范围在2至10纳米之间,缓冲液、血液和尿液样本中的检测限分别计算为0.43 nM、0.54 nM和0.62 nM(R = 0.98)。使用该方法进行癌症监测评估可能是一种简单、快速且经济高效的技术。
Cochrane Database Syst Rev. 2025-6-19
Health Technol Assess. 2006-9
Cochrane Database Syst Rev. 2022-3-2
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2021-10-29
Cochrane Database Syst Rev. 2022-9-26
Cochrane Database Syst Rev. 2020-10-19
Front Oncol. 2024-3-25
Anal Chim Acta. 2024-3-22
CA Cancer J Clin. 2024
Pharmaceuticals (Basel). 2021-8-5